Aldeyra Therapeutics Inc (NASDAQ:ALDX) Reports Decline in Sellers; Strong Momentum for Longs

April 17, 2018 - By Clifton Ray

Investors sentiment decreased to 1.62 in Q4 2017. Its down 1.51, from 3.13 in 2017Q3. It fall, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.
Prelude Llc has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). State Street accumulated 22,669 shares. Blackrock holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 37,694 shares. Adage Prtnrs Group Limited Company has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Wells Fargo & Mn holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 13,540 shares. Northern Trust Corp holds 0% or 35,861 shares. Macquarie stated it has 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Deutsche Fincl Bank Ag stated it has 1,700 shares. Drw Securities Ltd Liability holds 0.01% or 12,000 shares. Massachusetts-based Fmr Ltd Liability Corp has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Millennium Mngmt Limited Com invested in 715,679 shares or 0.01% of the stock. Renaissance Tech Limited Liability reported 0% stake. 10,110 are owned by Morgan Stanley. Dimensional Fund Advisors L P has invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Acadian Asset Limited Liability Company has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

The stock of Aldeyra Therapeutics Inc (NASDAQ:ALDX) registered a decrease of 0.33% in short interest. ALDX’s total short interest was 306,000 shares in April as published by FINRA. Its down 0.33% from 307,000 shares, reported previously. With 94,400 shares average volume, it will take short sellers 3 days to cover their ALDX’s short positions. The short interest to Aldeyra Therapeutics Inc’s float is 8.45%.

The stock increased 1.43% or $0.1 during the last trading session, reaching $7.1. About 16,852 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since April 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $139.62 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics had 4 analyst reports since October 24, 2017 according to SRatingsIntel. Cantor Fitzgerald initiated the stock with “Buy” rating in Tuesday, October 24 report. The firm has “Buy” rating given on Thursday, March 29 by Cantor Fitzgerald. The company was maintained on Thursday, November 9 by Cantor Fitzgerald.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: